Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 73Rituximab 59Specimen Handling 49Biopsy 42Doxorubicin 41Vincristine 40Magnetic Resonance Spectroscopy 39Prednisone 36venetoclax 28obinutuzumab 27fludarabine 26ibrutinib 22Methotrexate 22Dexamethasone 21Cytarabine 21Lenalidomide 20blinatumomab 19Etoposide 19merphos 17zanubrutinib 16acalabrutinib 16prednylidene 15fludarabine phosphate 15deltacortene 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13CT-P10 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Irradiation × Lymphoid × 30 days × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡